A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 23, 2020

Primary Completion Date

September 1, 2025

Study Completion Date

August 3, 2027

Conditions
Frontotemporal Dementia
Interventions
DRUG

AL001

Administered via intravenous (IV) infusion

DRUG

Placebo

Administered via intravenous (IV) infusion

DRUG

Open label - AL001

Administered via intravenous (IV) infusion

Trial Locations (44)

2325

Fundación Para La Lucha Contra Las Enfermedades Neurológicas de La Infancia, Buenos Aires

3000

UZ Leuven, Leuven

3128

Box Hill Hospital, Box Hill

10032

Irving Institute for Clinical and Translational Research, New York

19104

University of Pennsylvania, Philadelphia

21205

Johns Hopkins University School of Medicine, Baltimore

30329

Emory University, Atlanta

34093

Istanbul University Medical Faculty, Istanbul

37232

Vanderbilt University Medical Center, Nashville

45219

University Of Cincinnati Gardner Neuroscience institute, Cincinnati

46202

Indiana University Health Neuroscience Center, Indianapolis

50937

Uniklinik Köln, Cologne

55905

Mayo Comprehensive Cancer Center - PPDS, Rochester

66205

University of Kansas Alzheimer's Disease Center, Fairway

68100

University General Hospital of Alexandroupolis - Department of Neurology, Alexandroupoli

77030

Houston Methodist Institute for Academic Medicine, Houston

80045

University of Colorado, Aurora

85013

Dignity Health, Phoenix

97239

Oregon Health and Science University, Portland

92093-0648

University of California San Diego, La Jolla

Unknown

The Queen Elizabeth Hospital, Woodville

The University of Western Ontario, London

Sunnybrook Research Institute - University of Toronto, Toronto

CHU de Bordeaux, Bordeaux

CHRU Lille, Lille

Groupe Hospitalier Pitié Salpétrière, Paris

Universitätsklinikum Ulm, Ulm

Nuovo Ospedale Civile S. Agostino-Estense di Baggiovara, Baggiovara

ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia, Brescia

IRCCS - Centro S. Giovanni di Dio Fatebenefratelli, Brescia

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan

Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta, Milan

PIA Fondazione Panico, Tricase

Erasmus MC, Rotterdam

Centro Hospitalar E Universitário de Coimbra EPE, Coimbra

Hospital CUF Descobertas, Lisbon

Hospital Clinic de Barcelona, Barcelona

Hospital Universitario de Donostia, Donostia / San Sebastian

Karolinska Universitetssjukhuset Huddinge - PPDS, Huddinge

Felix Platter Spital, Basel

University College London, London

115 28

Eginitio University General Hospital of Athens - 1st University Neurology Clinic, Athens

4099-001

Centro Hospitalar do Porto - Hospital de Santo António, Porto

1649-035

Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria, Lisbon

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Alector Inc.

INDUSTRY

NCT04374136 - A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) | Biotech Hunter | Biotech Hunter